Atlas Trials

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Clinical trial NCT06504524 · COMPLETED

Trial details

NCT number
NCT06504524
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Myeloma
Start date
2023-09-01
Primary completion
2024-05-31
Enrollment
633

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.